North Carolina is currently home to 2618 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Charlotte, North Carolina
Conditions: Atopic Dermatitis
Register for Updates
The Effects of a Nitrate Supplementation on Erectile Function
NCT06213077
Recruiting
Twenty (20) individuals to be recruited from Ballantyne Medical Associates in Charlotte, NC, without any significant chronic medical history. These patients are general patients for primary care that meet inclusion criteria. Patients will be screened and enrolled by Dr. Bauer and his delegated research staff upon patient consult. Patients will be informed of the purpose of the study including risks, benefits, and alternative treatments to the study. After the potential participants have been giv... Read More
Gender:
MALE
Ages:
Between 40 years and 65 years
Trial Updated:
01/16/2024
Locations: OnSite Clinical Solutions, Charlotte, North Carolina
Conditions: Erectile Dysfunction
Register for Updates
Diagnostic Performance of Small RNA Blood Test in Patients Undergoing Follow-up Imaging After Positive Low Dose CT Screening for Cancer of the Lung
NCT05987189
Recruiting
2,000 individuals, aged 50-80 who have received a lung-RADS category 3 or 4 result on a LDCT screening study and who are scheduled for follow-up diagnostic imaging study, biopsy, clinical consultation or surgical appointment at one of the participating hospitals.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
01/12/2024
Locations: Duke University Health System, Durham, North Carolina
Conditions: Lung Cancer
Register for Updates
Evaluation of Telehealth Services on Mental Health Outcomes for People With Intellectual and Developmental Disabilities
NCT05336955
Recruiting
Roughly 40% of those with intellectual and developmental disabilities (IDD) have mental health needs, which is twice the national average. Nevertheless, there is dearth of evidenced-based mental health treatment for youth and young adults with IDD. The disparity in access to mental health care places those with IDD at greater risk of crisis service use. While telemental health studies demonstrate potential to enhance access to care, little of this research includes those with IDD, or crisis prev... Read More
Gender:
ALL
Ages:
Between 12 years and 45 years
Trial Updated:
01/12/2024
Locations: NC West, Concord, North Carolina
Conditions: Mental Health Conditions, Developmental Disability
Register for Updates
C-Brace Prospective Registry
NCT04640584
Recruiting
To gather prospective safety and effectiveness data for the C-Brace System following the standard of care.
Gender:
ALL
Ages:
All
Trial Updated:
01/09/2024
Locations: Reliable P&O, Jacksonville, North Carolina
Conditions: Pareses, Lower Extremity
Register for Updates
Registry of Patients With Acute/Subacute Type B Aortic Dissection Treated by Means of the STABILISE Technique (STABILISE)
NCT03707743
Recruiting
The aim of the study is to evaluate results of patients treated with the STABILISE technique for acute/subacute aortic dissection. Results and postoperative events are reported in accordance with the current reporting standards for endovascular aortic repair prepared and revised by the Ad Hoc Committee for Standardized Reporting Practices in Vascular Surgery of The Society for Vascular Surgery/American Association for Vascular Surgery
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: UNC Hospitals, Chapel Hill, North Carolina
Conditions: Aortic Dissection
Register for Updates
BlueWind RENOVA iStim™ System for the Treatment of OAB
NCT03596671
Recruiting
The OASIS study is prospective, interventional, multi-center study to evaluate the safety and efficacy of the BlueWind RENOVA iStim™ implantable tibial neuromodulation System for the treatment of patients diagnosed with overactive bladder.
Gender:
FEMALE
Ages:
Between 18 years and 80 years
Trial Updated:
12/29/2023
Locations: Duke Urogynecology, Durham, North Carolina
Conditions: Treatment of Patients Suffering From Overactive Bladder (OAB)
Register for Updates
The Mobility Toolkit: Electronically Augmented Assessment of Functional Recovery Following Lower-extremity Trauma
NCT04047030
Recruiting
The study will prospectively enroll and follow 300 participants ages 18-60 surgically treated for a lower-extremity articular injury including fractures of the tibial plateau, pilon, ankle, and calcaneus.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
12/22/2023
Locations: Mission Hospital, Asheville, North Carolina
Conditions: Gait
Register for Updates
A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors
NCT04775485
Recruiting
FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.
Gender:
ALL
Ages:
Between 6 months and 25 years
Trial Updated:
12/21/2023
Locations: Duke Cancer Center, Durham, North Carolina
Conditions: Low-grade Glioma, Advanced Solid Tumor
Register for Updates
Comparing Intact and Residual Amputated Muscle
NCT06182202
Recruiting
Lower limb amputees rely on their prosthetic to remain active and lead an independent life. In recent years, measuring residual muscle activity has been used to interpret a user's intent and thereby modulate prosthesis control. However, little knowledge is held on how residual muscle activity differs from non-amputated muscle. The research team will analyze and compare neuromuscular physiology in non-amputee individuals and amputees' non-amputated and residual muscles across functional tasks to... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
12/19/2023
Locations: North Carolina State University, Raleigh, North Carolina
Conditions: Amputation
Register for Updates
Improving Balance and Energetics of Walking Using a Hip Exoskeleton
NCT05447884
Recruiting
Robotic lower limb exoskeletons aim to improve or augment limb functions. Automatic modulation of robotic assistance is very important because it can increase the assistive outcomes and guarantee safety when using exoskeletons. However, this automatic assistance adjustment is challenging due to person-to-person and day-to-day variations, as well as the time-varying complex human-machine-interaction forces. In recent years, human-in-the-loop optimization methods have been investigated to reduce... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
12/19/2023
Locations: North Carolina State University, Raleigh, North Carolina
Conditions: Stroke
Register for Updates
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT04197687
Recruiting
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery. It also studies why some HER2 positive breast cancer patients respond better to chemotherapy in combination with trastuzumab and pertuzumab. TPIV100 is a type of vaccine made from HER2 peptide that may help the body build an effective immune response to kill tumor cells that express HER2. Sargramostim... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/15/2023
Locations: FirstHealth of the Carolinas-Moore Regional Hospital, Pinehurst, North Carolina
Conditions: Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Register for Updates